OncoMatch/Clinical Trials/NCT05722418
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Is NCT05722418 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CB-011 for relapsed/refractory multiple myeloma.
Treatment: CB-011 — This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: anti-cd38 monoclonal antibody
Cannot have received: car-t cell therapy
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- CU Anschutz Medical Campus, Anshutz Cancer Pavillion · Aurora, Colorado
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics · Miami, Florida
- University of Kentucky/ Markey Cancer Center · Lexington, Kentucky
- Hackensack Meridian John Theurer Cancer Center · Hackensack, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify